Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
- 1 May 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (6), 543-551
- https://doi.org/10.1016/s1470-2045(13)70125-6
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509Journal of Thoracic Oncology, 2011
- Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du MyélomeEuropean Journal of Haematology, 2011
- Markers for the non-invasive diagnosis of mesothelioma: a systematic reviewBritish Journal of Cancer, 2011
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307Journal of Thoracic Oncology, 2010
- Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Serum and pleural fluid biomarkers for mesotheliomaCurrent Opinion in Pulmonary Medicine, 2009
- Non-invasive diagnosis of pleural malignancies: The role of tumour markersLung Cancer, 2008
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971